We are live on
!
Find out more
SCM
Suvretta Capital Management Portfolio holdings
AUM
$3.92B
1-Year Est. Return
86.67%
This Fund
S&P 500
This Quarter
Est. Return
+19.42%
1 Year Est. Return
+86.67%
3 Year Est. Return
+295.96%
5 Year Est. Return
+364.48%
10 Year Est. Return
+2,073.65%
AUM
$1.87B
AUM Growth
-$497M
(-21%)
Cap. Flow
-$687M
Cap. Flow
% of AUM
-36.73%
Top 10 Holdings %
Top 10 Hldgs %
40.72%
Holding
114
New
19
Increased
26
Reduced
20
Closed
14
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Las Vegas Sands
LVS
|
+$40.5M |
| 2 |
Global Payments
GPN
|
+$28.9M |
| 3 |
NVIDIA
NVDA
|
+$25.7M |
| 4 |
TERN
Terns Pharmaceuticals
TERN
|
+$24.6M |
| 5 |
Zura Bio
ZURA
|
+$22.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
UnitedHealth
UNH
|
+$74.5M |
| 2 |
Elevance Health
ELV
|
+$70.3M |
| 3 |
Estee Lauder
EL
|
+$56.4M |
| 4 |
Colgate-Palmolive
CL
|
+$54.4M |
| 5 |
Yum! Brands
YUM
|
+$52.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 61.36% |
| 2 | Technology | 11.67% |
| 3 | Consumer Discretionary | 8.46% |
| 4 | Communication Services | 5.69% |
| 5 | Financials | 4.69% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
InflaRx
IFRX
$261M
| $25.6M | 1.37% |
5,733,910
+3,587,670
| +167% | +$16.1M |
|
27
Ultragenyx Pharmaceutical
RARE
$2.46B
| $25M | 1.34% |
541,480
-75,000
| -12% | -$3.48M |
|
28
TSMC
TSM
$2.15T
| $23.9M | 1.28% |
+237,031
| New | +$22.1M |
|
|
29
Zura Bio
ZURA
$536M
| $23.4M | 1.25% |
+2,850,000
| New | +$22.9M |
|
30
Capital One
COF
$136B
| $21.7M | 1.16% |
198,570
-9,030
| -4% | -$904K |
|
31
Accenture
ACN
$104B
| $21.6M | 1.16% |
+70,103
| New | +$20.4M |
|
32
GE Aerospace
GE
$396B
| $21.2M | 1.13% |
+241,496
| New | +$19.6M |
|
33
Canadian Pacific Kansas City
CP
$80.4B
| $20.9M | 1.12% |
259,073
-239,737
| -48% | -$18.9M |
|
34
Goldman Sachs
GS
$313B
| $20.3M | 1.09% |
63,091
+5,456
| +9% | +$1.79M |
|
35
Fulcrum Therapeutics
FULC
$288M
| $18.9M | 1.01% |
5,718,881
+541,171
| +10% | +$1.59M |
|
|
DFS
36
DELISTED
Discover Financial Services
DFS
| $18.8M | 1.01% |
+161,056
| New | +$16.9M |
|
|
KALV
37
DELISTED
KalVista Pharmaceuticals
KALV
| $18.3M | 0.98% |
2,034,506
+51,327
| +3% | +$473K |
|
38
Wells Fargo
WFC
$270B
| $18.1M | 0.97% |
423,506
+87,631
| +26% | +$3.53M |
|
39
Pinterest
PINS
$13.1B
| $18M | 0.96% |
658,390
-249,170
| -27% | -$6.21M |
|
|
KZR
40
DELISTED
Kezar Life Sciences
KZR
| $17.6M | 0.94% |
716,759
+28,000
| +4% | +$729K |
|
|
ATVI
41
DELISTED
Activision Blizzard
ATVI
| $17.5M | 0.93% |
+207,188
| New | +$16.8M |
|
42
Hilton Worldwide
HLT
$73B
| $16.7M | 0.89% |
114,862
-307,232
| -73% | -$43.7M |
|
|
WWE
43
DELISTED
World Wrestling Entertainment
WWE
| $16.3M | 0.87% |
+150,008
| New | +$15.5M |
|
44
Celsius Holdings
CELH
$7.45B
| $14.4M | 0.77% |
+288,645
| New | +$11.5M |
|
45
Johnson & Johnson
JNJ
$621B
| $13.7M | 0.73% |
82,800
+27,510
| +50% | +$4.44M |
|
46
Marvell Technology
MRVL
$189B
| $13.6M | 0.73% |
226,873
-62,427
| -22% | -$3.03M |
|
47
Agios Pharmaceuticals
AGIO
$1.89B
| $12.9M | 0.69% |
454,000
| – | – |
|
48
Sana Biotechnology
SANA
$977M
| $12.6M | 0.67% |
2,113,800
| – | – |
|
49
Union Pacific
UNP
$176B
| $12.5M | 0.67% |
61,152
-180,429
| -75% | -$35.9M |
|
|
RETA
50
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| $11.1M | 0.59% |
108,832
+93,732
| +621% | +$8.87M |
|
Similar funds
MIM
BCP
AS
MSI
FLSM
LWCA
GAMH
TFM
Suvretta Capital Management's Q2 2023 Portfolio in Review
As of Q2 2023, Suvretta Capital Management held 114 positions worth $1.87B, down 21% from $2.37B the previous quarter. Its ten largest holdings account for 41% of the portfolio.
Suvretta Capital Management withdrew a net $687M in Q2 2023, closing 14 positions and reducing 20 holdings. Its most notable exit was Estee Lauder, an estimated $56.4M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 61% of assets, up from 47% a quarter earlier, followed by Technology and Consumer Discretionary.
Against the trend, Suvretta Capital Management opened a new position in Las Vegas Sands worth $39.7M.
- Suvretta Capital Management's largest Q2 2023 buy was Las Vegas Sands: 685,233 shares worth $39.7M.
- Suvretta Capital Management added most to Terns Pharmaceuticals in Q2 2023, an estimated $24.6M increase.
- Suvretta Capital Management's biggest Q2 2023 reduction was UnitedHealth, cutting an estimated $74.5M.
- Suvretta Capital Management fully exited Estee Lauder in Q2 2023, selling an estimated $56.4M.
- Suvretta Capital Management's ten largest holdings make up 41% of its $1.87B portfolio in Q2 2023.
- Suvretta Capital Management opened 19 new positions and closed 14 in Q2 2023.
- Suvretta Capital Management's portfolio value fell 21% quarter-over-quarter to $1.87B.
Based on Suvretta Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.